Sections |
| Title | Starting Page | Number of Pages |
|---|
| MarketWatch | 1 | 1 |
| In this month's MarketWatch... | 1 | 1 |
| THIS MONTH'S HIGHLIGHTS | 2 | 1 |
| Key Biotechnology Announcements, October 15, 2007-November 14, 2007 | 2 | 1 |
| Gilead's drug | 2 | 1 |
| Gilead submits applications to FDA rejects Cortex's ADHD ImClone and Bristol-Myers sign BioWa extends technology Bioenvision | 2 | 1 |
| MedImmune | 2 | 1 |
| Genzyme | 2 | 1 |
| Biotechnology News Round-up | 2 | 2 |
| Research and Development | 4 | 1 |
| R&D News Headlines October 15, 2007-November 14, 2007 | 4 | 1 |
| Research Update | 4 | 1 |
| Results Update | 4 | 1 |
| US extends Imvamune smallpox vaccine trials | 4 | 1 |
| Allos starts Phase I trial in solid tumors | 4 | 1 |
| BioCryst starts enrollment for forodesine HCL trial | 5 | 1 |
| Critical starts patient enrollment for Phase III study of Zyflo | 5 | 1 |
| Results Update | 6 | 1 |
| Listeria vaccine for cervical cancer found safe | 6 | 1 |
| CuraGen's Velafermin misses trial goals | 6 | 1 |
| Exelixis drug disappoints in Phase II trial | 7 | 1 |
| Gilead's drug promising in hepatitis B | 7 | 1 |
| Regulatory | 8 | 1 |
| Opinion | 8 | 1 |
| Abraxis: clear regulatory pathway for Abraxane in lung cancer | 8 | 1 |
| Regulatory News Headlines October 15, 2007-November 14, 2007 | 9 | 1 |
| Applications Update | 9 | 1 |
| Decisions Update | 9 | 2 |
| Gilead submits applications to market VireadLev Pharmaceuticals amends CinryzeBLA | 9 | 1 |
| Lexicon files IND for rheumatoid arthritis drug | 10 | 1 |
| First generic versions of Trileptal get FDA approval | 10 | 1 |
| Cephalon submits SNDA for Fentora | 10 | 1 |
| FDA rejects Cortex's ADHD study | 10 | 1 |
| Sequella lead drug for TB gets orphan status | 11 | 1 |
| FDA seeks more information on Theravance's antibiotic | 11 | 1 |
| Alliances & Licensing | 12 | 1 |
| Alliances News Headlines October 15, 2007-November 14, 2007 | 12 | 1 |
| Licensing Update | 12 | 2 |
| Alliances Update | 12 | 1 |
| Elastin Specialties to partner with Novozymes | 12 | 1 |
| Altair Therapeutics to focus on Isis antisense drugs | 12 | 1 |
| ImClone and Bristol-Myers sign co- development deal with Merck | 13 | 1 |
| Iroko acquires Canadian rights to Eli Lilly's Vancocin | 13 | 1 |
| Novavax and Allergan terminate agreement for Estrasorb | 13 | 1 |
| BioWa extends technology licensing with MedImmune | 14 | 1 |
| Organon signs licencing deal with Endotis for antithrombotic drugs | 14 | 1 |
| Immunosyn signs amended license agreement | 14 | 1 |
| Company Strategy Opinion | 15 | 1 |
| Stada: biosimilars need different marketing strategy | 15 | 1 |
| BioMarin Pharmaceuticals: Kuvan set for successful launch | 16 | 1 |
| Company Strategy Headlines October 15, 2007-November 14, 2007 | 17 | 1 |
| Mergers & Acquisitions Update | 17 | 1 |
| Corporate News Update | 17 | 2 |
| Bioenvision shareholders approve acquisition by Genzyme | 17 | 1 |
| Avant and Celldex to merge operations | 17 | 1 |
| Novozymes to acquire Philom Bios | 18 | 1 |
| Bio-Bridge Science to acquire Lanzhou Roya Biotechnology | 18 | 1 |
| Genzyme launches Cholestagel in Europe | 18 | 1 |
| Tapestry to cut non-clinical work force | 19 | 1 |
| OSI Pharma posts 77% rise in Q3 revenues | 19 | 1 |
| Cambridge Antibody to change name to MedImmune | 20 | 1 |
| COMPANY SPOTLIGHT-Amgen | 21 | 6 |
| FURTHER READING | 27 | 1 |
| INDEX | 28 | 2 |
